Maria-Helene Lafeuille, MA

Real-world Comparison of Adherence Between Patients with Chronic Lymphocytic Leukemia Treated with Single-agent Ibrutinib or Acalabrutinib In First Line

Introduction:Ibrutinib and acalabrutinib are both Bruton‚Äôs tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Since st...

Bruno Emond , MA;

Laura Morrison , MPH;

Maria-Helene Lafeuille , MA;

Xiaoxiao Lu ;

Frederic Kinkead ;

Wasiulla Khan ;

Patrick Lefebvre , MA;

Linda Wu ;

Zaina P. Qureshi ;

Ryan Jacobs ;

11/04/2022

Hospitalizations, Emergency Room Visits and Adherence Among Patients With Schizophrenia Initiated on Long-Acting Injectable Versus Oral Antipsychotics: A Systematic Review and Meta-Analysis

Long-acting injectable (LAI) antipsychotics, compared with oral antipsychotics (OA), have the potential to increase medication adherence in adult patients with schizophrenia. This increas...

Maria-Helene Lafeuille , MA;

Philippe Thomas-Leduc , MSc;

Isabelle Ghelerter ;

Patrick Lefebvre , MA;

Ha Nguyen , BA;

Dee Lin , PharmD, MS;

Panagiotis Mavros , PhD;

Carmella Benson , MSc, MS, MSHP;

10/08/2020

Medication Adherence, Healthcare Resource Utilization, and Costs Among Medicaid Beneficiaries With Schizophrenia Treated With Once-monthly Paliperidone Palmitate or Once-every-three-months Paliperidone Palmitate

Background: Antipsychotics with reduced dosing frequency may improve adherence and clinical outcomes for patients with schizophrenia. This study compared adherence, persistence, healthcar...

Maryia Zhdanava , MA;

Maria-Helene Lafeuille , MA;

Kruti Joshi , MPH, MD;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Aurelie Cote ;

Maude Vermette-Laforme , BSc;

10/08/2020

Risk of Subsequent Relapses and Corresponding Healthcare Costs Among Recently-Relapsed Medicaid Patients With Schizophrenia

BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...

Edward S. Kim , MD, FACP, MBA;

Patrick Lefebvre , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

Bruno Emond , MA;

Charmi Patel , BS , RN, BSN, MPH;

Laura Morrison , MPH;

Maria-Helene Lafeuille , MA;

11/22/2019

Prevalence, Incidence and Economic Burden of Schizophrenia Among Medicaid Beneficiaries

Background: Schizophrenia carries a substantial economic burden to healthcare systems and payers. This study aims to update the prevalence, incidence and economic burden of schizophrenia ...

Charmi Patel , BS , RN, BSN, MPH;

Maryia Zhdanava , MA;

Maria-Helene Lafeuille , MA;

Patrick Lefebvre , MA;

Aurélie Côté-Sergent , MSc;

Dominic Pilon , MA;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

11/22/2019

Recent Patterns of Relapse and Associated Costs in Schizophrenia Patients Initiating Atypical Antipsychotics

BACKGROUND: Data on the burden associated with schizophrenia relapse within the new treatment landscape is scarce. This study aims to identify relapse in schizophrenia and update their as...

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Charmi Patel , BS , RN, BSN, MPH;

Dee Lin , PharmD, MS;

Kruti Joshi , MPH, MD;

Maria-Helene Lafeuille , MA;

Aurélie Côté-Sergent , MSc;

11/22/2019